Here's Why Intuitive Surgical Toppled Despite Exceeding Quarterly Views
Here's Why Intuitive Surgical Toppled Despite Exceeding Quarterly Views
Intuitive Surgicalon Thursday reported another tepid quarter for procedure growth using its da Vinci robotic surgery system — prodding ISRG stock to tumble.
直覺外科週四報告了又一個不温不火的季度手術增長，使用其達芬奇機器人手術系統？歐元“刺激ISRG股票暴跌。
The robotic surgery systems maker has been hamstrung amid the coronavirus pandemic as patients put off elective surgeries. During the fourth quarter, procedures using Intuitive Surgical's biggest robotic surgery system rose just 6%.
這家機器人手術系統製造商在冠狀病毒大流行中陷入癱瘓，因為患者推遲了選擇性手術。在第四季度，使用直覺外科最大的機器人手術系統的手術僅增長了6%。
The coronavirus pandemic has impacted Intuitive Surgical differently depending on the region.
冠狀病毒大流行對直覺外科的影響因地區而異。
"In the U.S., for example, while da Vinci procedures have recovered a significant portion of the pre-Covid-19 levels, the resurgence of Covid-19 in some states has had, and will likely continue to have, an adverse impact on the company's procedure volumes," Intuitive Surgical said in a news release.
直覺外科在一份新聞稿中説：“例如，在美國，雖然達芬奇手術已經恢復了很大一部分新冠肺炎之前的水平，但新冠肺炎在一些州的復興已經並可能繼續對公司的手術量產生不利影響。”
In after-hours trading on the stock market today, ISRG stock skidded 2.1% near 782.ISRG Stock Dips On Procedure Growth
在今日股市盤後交易中，ISRG股價下滑2.1%，接近782.ISRG股價因程序性增長而下跌
The fourth quarter represents a slowdown for procedure growth. In the second quarter, procedures plummeted 19%. They recovered somewhat in the third quarter, growing 7%. But the fourth-quarter 6% growth rate slammed ISRG stock in late action.
第四季度代表着程序增長放緩。在第二季度，程序驟降了19%。他們在第三季度有所回升，增長了7%。但第四季度6%的增長率在尾盤重創了ISRG的股票。
Further, Intuitive Surgical shipped 3% fewer da Vinci systems in the quarter than it did in the year-ago period. That also didn't help ISRG stock.
此外，直覺外科公司本季度的達芬奇系統出貨量比去年同期減少了3%。這也沒有提振ISRG的股票。
The remainder of Intuitive Surgical's earnings wasn't a surprise. In conjunction with the annual J.P. Morgan Healthcare Conference, Intuitive Surgical pre-announced its earnings on Jan. 13.
直覺外科的其餘收益並不令人意外。在一年一度的摩根大通醫療會議期間，直覺外科公司於1月13日預先公佈了收益。
Sales grew 4% to $1.33 billion. This was driven by growth in procedures but offset by fewer shipments of da Vinci systems. Adjusted earnings were $3.58 per share, up by a dime year over year. Both measures beat the estimate from FactSet for $1.25 billion in sales and profit of $3.12 a share.
銷售額增長4%，至13.3億美元。這是由程序的增長推動的，但被達芬奇系統出貨量的減少所抵消。調整後的每股收益為3.58美元，同比增長1美分。這兩項指標都超過了FactSet預計的12.5億美元的銷售額和每股3.12美元的利潤。
Follow Allison Gatlin on Twitter at @IBD_AGatlin.
在Twitter上關注艾莉森·加特林(Allison Gatlin)，郵箱是@ibd_agatlin。
YOU MAY ALSO LIKE:
您可能還喜歡：
Gilead Stock 2021: Why The Biotech Stock Isn't Depending On Covid Drugs
吉利德股票2021：為什麼生物技術股票不依賴Covid藥物
Is JNJ Stock A Buy As It Nears Phase 3 Covid Vaccine Test Results?
JNJ股票在得知第三階段Covid疫苗檢測結果時是買入的嗎？
Short-Term Trades Can Add Up To Big Profits. IBD's SwingTrader Shows You How
短期交易可以帶來豐厚的利潤。IBD的SwingTrader向你展示如何
IBD Stock Of The Day: See How To Find, Track And Buy The Best Stocks
IBD當日股票：瞭解如何查找、跟蹤和購買最好的股票
Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks
值得買入和關注的股票：頂級IPO、大盤和小盤股、成長股
譯文內容由第三人軟體翻譯。